MetaCap

Cocrystal Pharma (COCP) vs Pasithea Therapeutics (KTTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pasithea Therapeutics (KTTA) has outperformed Cocrystal Pharma (COCP) over the past year, gaining 63.9% versus a gain of 5.6%. Over five years, COCP leads with a -91.8% price change compared with -99.4% for KTTA. Cocrystal Pharma is the larger company by market cap ($18.3 million vs $17.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COCP+5.56%KTTA+63.94%
+424%+197%-30%
Nov 21, 20251 yearNov 20, 2026
COCP-90.35%KTTA-98.99%
+78%-15%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COCP versus KTTA key metrics
MetricCOCPKTTA
Share price$0.95$0.4787
Market cap$18.30M$17.59M
1-day change-2.05%-0.48%
YTD return-3.06%-62.89%
1-year return+5.56%+63.94%
5-year return-91.84%-99.40%
EPS (TTM)$-0.76$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-8.83M$-20.43M
52-week high$2.03$2.06
52-week low$0.76$0.32
Distance from 52-week high-53.20%-76.76%
Analyst consensusnonenone
Avg. price target upside+847.37%+526.70%
Average volume40.65K705.64K
Shares outstanding19.26M36.75M
Employees105
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KTTA has outperformed COCP by 58.4 percentage points over the past year.

About Cocrystal Pharma

COCP stock →

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About Pasithea Therapeutics

KTTA stock →

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

COCP vs KTTA FAQ

Which is bigger, Cocrystal Pharma or Pasithea Therapeutics?

Cocrystal Pharma (COCP) is larger, with a market capitalization of $18.30M compared with $17.59M for Pasithea Therapeutics (KTTA).

Which stock has performed better over the past year, COCP or KTTA?

KTTA returned +63.94% over the past 12 months, compared with +5.56% for COCP (price return, excluding dividends). Past performance does not predict future results.

Are Cocrystal Pharma and Pasithea Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons